Literature DB >> 19855290

Systemic high-sensitivity C-reactive protein level in pseudoexfoliation syndrome and pseudoexfoliation glaucoma.

Nurşen Yüksel1, Dilara Pirhan, Ozgül Altintaş, Yusuf Cağlar.   

Abstract

PURPOSE: To evaluate the systemic high sensitivity C-reactive protein (hsCRP) levels in patients with pseudoexfoliation syndrome (XFS) and pseudoexfoliation glaucoma (XFG).
MATERIALS AND METHODS: We prospectively examined 31 patients with XFS, 26 with XFG, and 25 controls. To the study patients with the exclusion of serious hypertension that do not have any cardiovascular and cerebrovascular disease and that diagnosed as XFS and XFG have been included. Each patient passed through a detailed blood sampling including hsCRP, biochemistry, and lipid profile. Plasma C-reactive protein (CRP) levels were measured with nephelometric method by using Beckman IMMAGE hsCRP reagent.
RESULTS: Each group had similar demographic parameters including age, sex, body mass index, heart rate, and blood pressure. When we compared with controls, there was no statistically significant difference in the hsCRP and biochemistry results between the 3 groups. When all patients with pseudoexfoliation (PEX) compared with controls there was no difference.
CONCLUSIONS: Our findings indicated no difference in the hsCRP level between XFS, XFG, and controls. This study suggests that CRP is not a predictive marker of inflammation and peripheral endothelial dysfunction in XFS, which is accepted as a systemic disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19855290     DOI: 10.1097/IJG.0b013e3181bdb570

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  11 in total

1.  Serum C-reactive protein levels in exfoliation syndrome and exfoliative glaucoma.

Authors:  M C Mocan; O Dikmetas; M Irkec
Journal:  Eye (Lond)       Date:  2011-07-08       Impact factor: 3.775

2.  Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome.

Authors:  K Türkyılmaz; V Öner; A Kırbas; M S Sevim; B Sekeryapan; G Özgür; M Durmus
Journal:  Eye (Lond)       Date:  2013-05-10       Impact factor: 3.775

3.  Elevated neutrophil-to-lymphocyte ratio in pseudoexfoliation syndrome.

Authors:  B E Kurtul; P A Ozer; E U Kabatas
Journal:  Eye (Lond)       Date:  2016-05-06       Impact factor: 3.775

4.  Evaluation of serum and aqueous humor klotho levels in pseudoexfoliation syndrome, pseudoexfoliation and primary open-angle glaucoma.

Authors:  Ecem Onder Tokuc; Nursen Yuksel; Hale Maral Kır; Esra Acar
Journal:  Int Ophthalmol       Date:  2021-03-18       Impact factor: 2.031

5.  The correlation between pseudoexfoliation syndrome and the Triglyceride-Glucose index.

Authors:  Rafiye Nur Abay; Zeynep Katipoğlu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-20       Impact factor: 3.117

6.  High-sensitivity C-reactive Protein and Tumor Necrosis Factor Alpha in Pseudoexfoliation Syndrome.

Authors:  Rana Sorkhabi; Amir Ghorbanihaghjo; Mohamadhossein Ahoor; Mehriar Nahaei; Nadereh Rashtchizadeh
Journal:  Oman Med J       Date:  2013-01

Review 7.  Pseudoexfoliation syndrome and cardiovascular diseases.

Authors:  Georgios K Andrikopoulos; Dimitrios K Alexopoulos; Sotirios P Gartaganis
Journal:  World J Cardiol       Date:  2014-08-26

8.  Cholesterol and glaucoma: a systematic review and meta-analysis.

Authors:  Laura Posch-Pertl; Monja Michelitsch; Gernot Wagner; Brigitte Wildner; Günther Silbernagel; Gudrun Pregartner; Andreas Wedrich
Journal:  Acta Ophthalmol       Date:  2021-01-28       Impact factor: 3.988

9.  Early-onset Pseudoexfoliation Syndrome following Multiple Intraocular Procedures.

Authors:  Heydar Amini; Ramin Daneshvar; Yadollah Eslami; Sasan Moghimi; Nima Amini
Journal:  J Ophthalmic Vis Res       Date:  2012-07

Review 10.  Cardiovascular repercussions of the pseudoexfoliation syndrome.

Authors:  Vasiliki Katsi; Antonios N Pavlidis; Manolis S Kallistratos; Athanasios Fitsios; Athanasios Bratsas; Dimitris Tousoulis; Christodoulos Stefanadis; Athanasios J Manolis; Ioannis Kallikazaros
Journal:  N Am J Med Sci       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.